

Medicines and Healthcare products Regulatory Agency

CERTIFICATE NUMBER : UK GMP 41432 Insp GMP 41432/6618812-0005[H]

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER(1),(2)

Part 1

Issued following an inspection in accordance with :

Regulation 331A of The Human Medicines Regulations 2012 (SI 2012/1916)

The competent authority of United Kingdom confirms the following :

The Manufacturer : RELIANCE LIFE SCIENCES PRIVATE LIMITED (PLANT 6)

Site address : RELIANCE LIFE SCIENCES PRIVATE LIMITED (PLANT 6) , DHIRUBHAI AMBANI LIFE SCIENCE CENTRE (DALC),
THANE, BELAPUR ROAD, RABALE, NAVI MUMBAI, IN-400701, INDIA

Has been inspected in connection with marketing authorisation(s) listing manufacturers located outside of the European Economic Area in accordance with Part 16 of The Human Medicines Regulations 2012 (SI 2012/1916)

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 06/08/2018, it is considered that it complies with

- The principles and guidelines of Good Manufacturing Practice laid down in Regulation B17 of the Human Medicines Regulations 2012 (as amended)

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in MHRA-GMDP. If it does not appear, please contact the issuing authority.

- (1) Guidance on the interpretation of this template can be found in the Help menu of MHRA-GMDP database.
- (2) These requirements fulfil the GMP recommendations of WHO.

Part 2

Human Medicinal Products

1. MANUFACTURING OPERATIONS

[1.1] Sterile Products

[1.1.1] Aseptically prepared (processing operations for the following dosage forms)

[1.1.1.2] Lyophilisates

[1.2] Non-sterile products

[1.2.1] Non-Sterile Products (processing operations for the following dosage forms)

[1.2.1.1] Capsules, hard shell

[1.2.1.13] Tablets

[1.4] Other products or manufacturing activity

[1.4.2] Sterilisation of active substances/excipients/finished products:

[1.4.2.1] Filtration

[1.5] Packaging

[1.5.2] Secondary packaging

[1.6] Quality control testing

[1.6.1] Microbiological: sterility

[1.6.2] Microbiological: non-sterility

[1.6.3] Chemical/Physical

Restrictions or Remarks

Plant 6 only is approved for the manufacture and packaging of non-sterile oncology products and sterile product manufacture is approved on Fourth Floor of Plant 6. Dispensing of API in Plant 3 and the use of the Central Store building are approved. QC testing in Plant 3, Stability chambers located in the 'South Block' building, Sterility and associated QC testing on second floor of North Block are approved. Note: The approval to manufacture products includes approval for primary packaging of the product.

08/02/2019	Name and signature of the authorised person of the Competent Authority of United Kingdom
	Confidential
	Medicines and Healthcare products Regulatory Agency
	Tel : Confidential